Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI in Advanced Duodenal-Pancreatic Endocrine Tumors
NCT00416767Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- May 2004
- Primary completion
- Jan 2006
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan and folinic acid in Neuroendocrine Neoplasm (NEN), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-Free Survival Rate at 6 months. Started May 2004; status: completed.
02
Drugs
fluorouracilirinotecanfolinic acid
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00416767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416767.